

**Binh Dinh Pharmaceutical and Medical Equipment  
Joint Stock Company (BIDIPHAR)**

Separate financial statements

For the year ended 31 December 2025



# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

## CONTENTS

	<i>Pages</i>
General information	1 - 2
Report of the management	3
Independent auditors' report	4 - 5
Separate balance sheet	6 - 7
Separate income statement	8
Separate cash flow statement	9 - 10
Notes to the separate financial statements	11 - 39

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

## GENERAL INFORMATION

### THE COMPANY

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) ("the Company") was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QD-UBND on 23 June 2010 and the first Enterprise Registration Certificate ("ERC") No. 4100259564 issued by Department of Planning and Investment ("DPI") of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14<sup>th</sup> amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares are listed on the Ho Chi Minh City Stock Exchange ("HOSE") with trading code as DBD in accordance with License No. 185/QD-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Company are manufacturing and trading in pharmaceutical products and medical equipment.

The Company's registered head office is located at 498 Nguyen Thai Hoc, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has seventeen (17) branches located at other province, cities within Vietnam.

### BOARD OF DIRECTORS

The members of the Board of Directors during the year and at the date of this report are:

Mr Ta Nam Binh	Chairman/ Independent member
Mr Nguyen Tien Hai	Member
Ms Pham Thi Thanh Huong	Member
Mr Nguyen Ngoc Dung	Member
Mr Truong Thanh Liem	Member
Mr Phan Tan Thu	Member
Ms Nguyen Thi Minh Giang	Independent member

### INTERNAL AUDIT COMMITTEE UNDER BOARD OF DIRECTORS

The members of the Audit Committee under the Board of Directors during the year and at the date of this report are:

Ms Nguyen Thi Minh Giang	Chairwoman
Mr Phan Tan Thu	Member

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

GENERAL INFORMATION (continued)

## **MANAGEMENT**

The members of the Management during the year and at the date of this report are:

Ms Pham Thi Thanh Huong	General Director
Mr Nguyen Ngoc Dung	Deputy General Director
Ms Banh Thi Ngoc Quynh	Deputy General Director

## **LEGAL REPRESENTATIVE**

The legal representative of the Company during the year and at the date of this report is Ms Pham Thi Thanh Huong.

## **AUDITOR**

The auditor of the Company is Ernst & Young Vietnam Limited.

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

## REPORT OF THE MANAGEMENT

The management of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) ("the Company") is pleased to present this report and the separate financial statements of the Company for the year ended 31 December 2025.

### THE MANAGEMENT'S RESPONSIBILITY IN RESPECT OF THE SEPARATE FINANCIAL STATEMENTS

The management is responsible for the separate financial statements of each financial year which give a true and fair view of the separate financial position of the Company and of the results of its operations and its separate cash flows for the year. In preparing those separate financial statements, management is required to:

- ▶ select suitable accounting policies and then apply them consistently;
- ▶ make judgements and estimates that are reasonable and prudent;
- ▶ state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the separate financial statements; and
- ▶ prepare the separate financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue its business.

The management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the separate financial position of the Company and to ensure that the accounting records comply with the applied accounting system. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The management confirmed that it has complied with the above requirements in preparing the accompanying separate financial statements.

### STATEMENT BY THE MANAGEMENT

The management does hereby state that, in its opinion, the accompanying separate financial statements give a true and fair view of the separate financial position of the Company as at 31 December 2025 and of the separate results of its operations and its separate cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the separate financial statements.

The Company has subsidiaries as disclosed in the separate financial statements. The Company prepared these separate financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System, and the relevant legal regulations on the preparation and presentation of separate financial statements. In addition, the Company has also prepared the consolidated financial statements of the Company and its subsidiaries for the year ended 31 December 2025 dated 20 March 2026 in accordance with the above prevailing regulations on the preparation and presentation of consolidated financial statements.

Users of the separate financial statements should read them together with the said consolidated financial statements in order to obtain full information on the consolidated financial position, consolidated results of operations and consolidated cash flows of the Company and its subsidiaries.

For and on behalf of the management:



Phạm Thị Thanh Hương  
General Director

Gia Lai Province, Vietnam

20 March 2026



**Shape the future  
with confidence**

Reference: 12315209/68628197

## **INDEPENDENT AUDITORS' REPORT**

**To: The Shareholders of Binh Dinh Pharmaceutical and Medical Equipment  
Joint Stock Company (BIDIPHAR)**

We have audited the accompanying separate financial statements of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) ("the Company"), as prepared on 20 March 2026 and set out on pages 6 to 39, which comprise the separate balance sheet as at 31 December 2025, the separate income statement and the separate cash flow statement for the year then ended and the notes thereto.

### ***The Management's responsibility***

The Company's management is responsible for the preparation and true and fair presentation of these separate financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the separate financial statements, and for such internal control as management determines is necessary to enable the preparation and presentation of the separate financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' responsibility***

Our responsibility is to express an opinion on these separate financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the separate financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the separate financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the separate financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Company's preparation and true and fair presentation of the separate financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the separate financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Shape the future  
with confidence

**Opinion**

In our opinion, the separate financial statements give a true and fair view, in all material respects, of the separate financial position of the Company as at 31 December 2025, and of the results of its separate operations and its separate cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the separate financial statements.

**Ernst & Young Vietnam Limited**



---

Phạm Thị Cam.Tu  
Deputy General Director  
Audit Practicing Registration Certificate  
No. 2266-2023-004-1



---

Tran Thanh Thuy  
Auditor  
Audit Practicing Registration Certificate  
No. 3076-2024-004-1

Ho Chi Minh City, Vietnam

20 March 2026

SEPARATE BALANCE SHEET  
as at 31 December 2025

VND

Code	ASSETS	Notes	Ending balance	Beginning balance
<b>100</b>	<b>A. CURRENT ASSETS</b>		<b>1,424,724,636,193</b>	<b>1,429,358,705,624</b>
<b>110</b>	<b>I. Cash and cash equivalents</b>	<b>4</b>	<b>188,591,213,418</b>	<b>302,102,399,732</b>
111	1. Cash		53,591,213,418	52,602,399,732
112	2. Cash equivalents		135,000,000,000	249,500,000,000
<b>120</b>	<b>II. Short-term investments</b>		<b>406,701,393,300</b>	<b>121,921,158,600</b>
121	1. Held-for-trading securities		1,393,300	1,393,300
123	2. Held-to-maturity investments	5	406,700,000,000	121,919,765,300
<b>130</b>	<b>III. Current accounts receivable</b>		<b>445,620,605,247</b>	<b>490,593,372,723</b>
131	1. Short-term trade receivables	6.1	459,313,853,193	475,715,676,078
132	2. Short-term advances to suppliers	6.2	40,788,245,884	76,429,428,383
136	3. Other short-term receivables	7	8,772,516,375	6,520,227,122
137	4. Provision for doubtful short-term receivables	8	(63,254,010,205)	(68,071,958,860)
<b>140</b>	<b>IV. Inventories</b>	<b>9</b>	<b>363,748,145,497</b>	<b>502,910,880,911</b>
141	1. Inventories		395,258,175,758	529,866,825,320
149	2. Provision for obsolete inventories		(31,510,030,261)	(26,955,944,409)
<b>150</b>	<b>V. Other current assets</b>		<b>20,063,278,731</b>	<b>11,830,893,658</b>
151	1. Short-term prepaid expenses	10	8,922,293,818	8,607,704,453
152	2. Value-added tax deductible		10,782,568,572	1,868,917,182
153	3. Tax and other receivables from the State	16	358,416,341	1,354,272,023
<b>200</b>	<b>B. NON-CURRENT ASSETS</b>		<b>1,079,252,754,203</b>	<b>750,859,089,873</b>
<b>220</b>	<b>I. Fixed assets</b>		<b>353,628,000,336</b>	<b>336,934,026,822</b>
221	1. Tangible fixed assets	11	271,388,883,361	280,110,093,082
222	Cost		848,778,504,684	809,920,845,684
223	Accumulated depreciation		(577,389,621,323)	(529,810,752,602)
227	2. Intangible fixed assets	12	82,239,116,975	56,823,933,740
228	Cost		103,210,817,688	76,110,993,392
229	Accumulated amortization		(20,971,700,713)	(19,287,059,652)
<b>240</b>	<b>II. Long-term asset in progress</b>		<b>539,128,321,292</b>	<b>232,783,623,387</b>
242	1. Construction in progress	13	539,128,321,292	232,783,623,387
<b>250</b>	<b>III. Long-term investments</b>	<b>14</b>	<b>129,381,582,971</b>	<b>129,381,582,971</b>
251	1. Investment in subsidiaries		35,000,000,000	35,000,000,000
252	2. Investment in an associate		92,868,048,000	92,868,048,000
253	3. Investments in other entities		3,513,534,971	3,513,534,971
254	4. Provision for long-term investments		(2,000,000,000)	(2,000,000,000)
<b>260</b>	<b>IV. Other long-term asset</b>		<b>57,114,849,604</b>	<b>51,759,856,693</b>
261	1. Long-term prepaid expenses	10	41,460,158,966	38,643,130,984
262	2. Deferred tax assets	29.3	15,654,690,638	13,116,725,709
<b>270</b>	<b>TOTAL ASSETS</b>		<b>2,503,977,390,396</b>	<b>2,180,217,795,497</b>

Binh Dinh Pharmaceutical and Medical Equipment  
Joint Stock Company (BIDIPHAR)

B01-DN

SEPARATE BALANCE SHEET (continued)  
as at 31 December 2025

VND

Code	RESOURCES	Notes	Ending balance	Beginning balance
<b>300</b>	<b>C. LIABILITIES</b>		<b>840,408,269,325</b>	<b>590,634,601,621</b>
<b>310</b>	<b>I. Current liabilities</b>		<b>567,847,376,961</b>	<b>447,723,498,276</b>
311	1. Short-term trade payables	15.1	204,291,934,145	152,345,441,312
312	2. Short-term advances from customers	15.2	15,420,769,106	15,964,527,341
313	3. Statutory obligations	16	52,133,799,394	27,237,108,049
314	4. Payables to employees		91,130,836,305	76,086,014,025
315	5. Short-term accrued expenses	17	23,952,641,017	18,248,986,313
319	6. Other short-term payables	18	9,591,362,925	8,681,086,654
320	7. Short-term loans	19	43,214,775,628	35,913,500,637
322	8. Bonus and welfare fund	20	128,111,258,441	113,246,833,945
<b>330</b>	<b>II. Non-current liabilities</b>		<b>272,560,892,364</b>	<b>142,911,103,345</b>
338	1. Long-term loan	19	132,000,000,000	28,000,000,000
342	2. Other long-term provision	3.13	7,790,562,288	7,267,083,725
343	3. Scientific and technological development fund	21	132,770,330,076	107,644,019,620
<b>400</b>	<b>D. OWNERS' EQUITY</b>		<b>1,663,569,121,071</b>	<b>1,589,583,193,876</b>
<b>410</b>	<b>I. Capital</b>	<b>22.1</b>	<b>1,661,326,937,330</b>	<b>1,587,175,359,771</b>
411	1. Share capital		945,293,470,000	935,938,470,000
411a	- Ordinary shares with voting rights		945,293,470,000	935,938,470,000
412	2. Share premium		20,921,442,000	20,921,442,000
415	3. Treasury share		(1,952,796,558)	(1,952,796,558)
418	4. Investment and development fund		230,880,981,458	201,686,964,998
421	5. Undistributed earnings		466,183,840,430	430,581,279,331
421a	- Undistributed earnings by the end of prior year		243,473,755,331	228,708,902,330
421b	- Undistributed earnings of the year		222,710,085,099	201,872,377,001
<b>430</b>	<b>II. Other funds</b>	<b>23</b>	<b>2,242,183,741</b>	<b>2,407,834,105</b>
431	1. Subsidized fund		719,369,206	38,936,237
432	2. Fund for fixed assets in use		1,522,814,535	2,368,897,868
<b>440</b>	<b>TOTAL LIABILITIES AND OWNERS' EQUITY</b>		<b>2,503,977,390,396</b>	<b>2,180,217,795,497</b>

Gia Lai Province, Vietnam  
20 March 2026



  
Le Thi Kieu My  
Preparer

  
Do Huy Phuong  
Chief Accountant

  
Pham Thi Thanh Huong  
General Director

SEPARATE INCOME STATEMENT  
for the year ended 31 December 2025

VND

Code	ITEMS	Notes	Current year	Previous year
01	1. Revenues from sale of goods and rendering services	24.1	1,865,297,612,813	1,740,554,933,937
02	2. Deductions	24.1	(75,240,459,887)	(82,622,992,054)
10	3. Net revenues from sale of goods and rendering services	24.1	1,790,057,152,926	1,657,931,941,883
11	4. Cost of goods sold and service rendered	25	(940,284,806,267)	(859,166,792,281)
20	5. Gross profits from sale of goods and rendering services		849,772,346,659	798,765,149,602
21	6. Finance income	24.2	46,732,476,331	43,112,561,107
22	7. Finance expenses	27	(13,579,878,453)	(16,004,651,055)
23	<i>In which: Interest expense</i>		(3,846,557,387)	(4,058,137,920)
25	8. Selling expenses	26	(397,843,883,285)	(385,686,363,721)
26	9. General and administrative expenses	26	(137,590,473,577)	(120,978,955,274)
30	10. Operating profit		347,490,587,675	319,207,740,659
31	11. Other income		367,482,854	1,071,897,913
32	12. Other expenses		(3,290,696,630)	(4,784,335,900)
40	13. Other loss		(2,923,213,776)	(3,712,437,987)
50	14. Accounting profit before tax		344,567,373,899	315,495,302,672
51	15. Current corporate income tax expense	29.1	(54,329,614,225)	(52,920,199,307)
52	16. Deferred tax income	29.3	2,537,964,929	5,340,941,441
60	17. Net profit after tax		292,775,724,603	267,916,044,806

Gia Lai Province, Vietnam  
20 March 2026



Le Thi Kieu My  
Preparer



Do Huy Phuong  
Chief Accountant



Pham Thi Thanh Huong  
General Director

SEPARATE CASH FLOW STATEMENT  
for the year ended 31 December 2025

VND

Code	ITEMS	Notes	Current year	Previous year
	<b>I. CASH FLOWS FROM OPERATING ACTIVITIES</b>			
<b>01</b>	<b>Accounting profit before tax</b>		<b>344,567,373,899</b>	<b>315,495,302,672</b>
	<i>Adjustments for:</i>			
02	Depreciation and amortization	28	50,867,179,027	48,014,021,405
03	Provisions		259,615,760	17,753,867,873
04	Foreign exchange losses arising from revaluation of monetary accounts denominated in foreign currency		103,878,871	245,498,185
05	Profits from investing activities		(41,579,156,569)	(41,358,419,295)
06	Interest expenses	27	3,846,557,387	4,058,137,920
07	Other adjustments		27,920,976,714	23,237,816,553
<b>08</b>	<b>Operating profit before changes in working capital</b>		<b>385,986,425,089</b>	<b>367,446,225,313</b>
09	Decrease (increase) in receivables		6,792,012,372	(28,206,830,555)
10	Decrease (increase) in inventories		134,608,649,562	(33,036,867,093)
11	Increase in payables		126,918,235,720	11,537,549,189
12	Increase in prepaid expenses		(3,131,617,347)	(1,993,124,277)
14	Interest paid		(3,706,362,387)	(4,190,082,920)
15	Corporate income tax paid	16	(23,719,245,066)	(59,737,183,898)
16	Other cash inflows from operating activities		2,870,749,417	2,474,736,062
17	Other cash outflows from operating activities		(21,292,804,362)	(9,028,940,537)
<b>20</b>	<b>Net cash flows from operating activities</b>		<b>605,326,042,998</b>	<b>245,265,481,284</b>
	<b>II. CASH FLOWS FROM INVESTING ACTIVITIES</b>			
21	Purchase and construction of fixed assets		(408,077,881,501)	(148,253,526,092)
23	Bank term deposits		(333,700,000,000)	(127,819,765,300)
24	Collection of bank term deposits		48,919,765,300	224,593,126,650
27	Interest and dividend received		38,999,803,826	37,900,108,316
<b>30</b>	<b>Net cash flows used in investing activities</b>		<b>(653,858,312,375)</b>	<b>(13,580,056,426)</b>
	<b>III. CASH FLOWS FROM FINANCING ACTIVITIES</b>			
31	Capital contribution	22.2	9,355,000,000	-
33	Drawdown of borrowings	19	259,894,808,772	60,379,701,637
34	Repayment of borrowings	19	(148,593,533,781)	(75,733,320,497)
36	Dividends paid	22.2	(185,628,543,075)	(9,933,200)
<b>40</b>	<b>Net cash flows used in financing activities</b>		<b>(64,972,268,084)</b>	<b>(15,363,552,060)</b>

Binh Dinh Pharmaceutical and Medical Equipment  
Joint Stock Company (BIDIPHAR)

B03-DN


SEPARATE CASH FLOW STATEMENT (continued)  
for the year ended 31 December 2025

VND

Code	ITEMS	Notes	Current year	Previous year
50	Net (decrease) increase in cash and cash equivalents		(113,504,537,461)	216,321,872,798
60	Cash and cash equivalents at beginning of year		302,102,399,732	85,801,721,026
61	Impact of exchange rate fluctuation		(6,648,853)	(21,194,092)
70	Cash and cash equivalents at end of year	4	188,591,213,418	302,102,399,732

Gia Lai Province, Vietnam  
20 March 2026

  
Le Thi Kieu My  
Preparer

  
Do Huy Phuong  
Chief Accountant

  
Pham Thi Thanh Huong  
General Director



NOTES TO THE SEPARATE FINANCIAL STATEMENTS  
as at 31 December 2025 and for the year then ended

## 1. CORPORATE INFORMATION

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) (“the Company”) was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QD-UBND on 23 June 2010 and the first Enterprise Registration Certificate (“ERC”) No. 4100259564 issued by Department of Planning and Investment (“DPI”) of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14<sup>th</sup> amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares were listed on the Ho Chi Minh City Stock Exchange (“HOSE”) with trading code as DBD in accordance with License No. 185/QD-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Company are manufacturing and trading in pharmaceutical products and medical equipment.

The Company's normal course of business cycle is 12 months.

The Company's registered head office is located at 498 Nguyen Thai Hoc, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has seventeen (17) branches located at other province/cities within Vietnam.

The number of the Company's employees as at 31 December 2025 was 1,341 employees (31 December 2024: 1,332 employees).

### *Corporate structure*

As at 31 December 2025, the Company invested in two (2) subsidiaries are Bidiphar Trading Company Limited and Bidiphar Organic Medicine Company Limited and an associate is Bidiphar Rubber Joint Stock Company (*Note 14*).

## 2. BASIS OF PREPARATION

### 2.1 *Purpose of preparing the separate financial statements*

The company has subsidiaries as disclosed in Note 14. The Company prepared these separate financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System, and the statutory requirements relevant to the preparation and presentation of separate financial statements. In addition, as required by these regulations, the Company has also prepared the consolidated financial statements of the Company and its subsidiary for the year ended 31 December 2025 dated 20 March 2026 in accordance with the above prevailing regulations on the preparation and presentation of consolidated financial statements.

Users of the separate financial statements should read them together with the said consolidated financial statements in order to obtain full information on the consolidated financial position, the consolidated results of operations and the consolidated cash flows of the Company and its subsidiaries.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**2. BASIS OF PREPARATION** (continued)

**2.2 Applied accounting standards and system**

The separate financial statements of the Company expressed in Vietnam dong ("VND"), are prepared in accordance with the Vietnamese Enterprise Accounting System and other Vietnamese Accounting Standards issued by the Ministry of Finance as per:

- ▶ Decision No. 149/2001/QD-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- ▶ Decision No. 165/2002/QD-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- ▶ Decision No. 234/2003/QD-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- ▶ Decision No. 12/2005/QD-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- ▶ Decision No. 100/2005/QD-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying separate financial statements, including their utilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the separate financial position and separate results of operations and separate cash flows of the Company in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

**2.3 Applied accounting documentation system**

The Company's applied accounting documentation system is the Computerized based.

**2.4 Fiscal year**

The Company's fiscal year applicable for the preparation of its financial statements starts on 1 January and ends on 31 December.

**2.5 Accounting currency**

The separate financial statements are prepared in VND which is also the Company's accounting currency.

**2.6 Accounting regulation issued but not yet effective**

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC providing guidance on the enterprise accounting regime ("Circular 99"), replacing Circular No. 200/2014/TT-BTC providing guidance on the enterprise accounting regime issued by the Ministry of Finance on 22 December 2014 and several other related regulations. Circular 99 takes effect from 1 January 2026 and applies to enterprises with a financial year beginning on or after 1 January 2026.

The Company is in the process of assessing the impact of Circular 99 on the preparation and presentation of its separate financial statements and will implement Circular 99 for the financial year ending 31 December 2026.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**3.1 Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of changes in value.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.2 Inventories**

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value. Net realizable value ("NRV") represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The perpetual method is used to record inventories, which are valued as follows:

Raw materials, tool and supplies and merchandise - actual cost on a weighted average basis.

Work-in-process and finished goods - cost of finished goods and work-in-process on a weighted average basis.

*Provision for obsolete inventories*

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, merchandise and other inventories owned by the Company, based on appropriate evidence of impairment available at the balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the separate income statement. When inventories are expired, obsolescence, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the separate income statement.

**3.3 Receivables**

Receivables are presented in the separate balance sheet at the carrying amounts due from customers and other debtors, after the provision for doubtful receivables.

The provision for doubtful receivables represents amounts of outstanding receivables at the balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administration expenses in the separate income statement. When bad debts are determined as unrecoverable and accountant writes off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the separate income statement.

**3.4 Tangible fixed assets**

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use.

Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the separate income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the separate income statement.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.5 Intangible fixed assets**

Intangible fixed assets are stated at cost less accumulated amortization.

The cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use.

Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the separate income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the separate income statement.

*Land use rights*

Land use rights are recorded as intangible fixed assets representing the value of the rights to use the lands acquired by the Company. The advance payment for land rental, of which the land lease contracts have effectiveness prior to 2003 and Land use rights certificate being issued, are recorded as intangible fixed asset according to Circular No. 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013 guiding the management, use and depreciation of fixed assets ("Circular 45").

The useful life of land use rights are assessed as either definite or indefinite. Accordingly, the land use rights with definite useful life representing the land lease are amortized over the lease term while the land use rights with indefinite useful lives is not amortized.

**3.6 Depreciation and amortization**

Depreciation of tangible fixed assets and amortization of intangible fixed assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	4 - 43 years
Machinery and equipment	4 - 12 years
Means of transportation	4 - 10 years
Office equipment	4 - 10 years
Land use rights	50 years
Computer software	4 - 10 years

**3.7 Construction in progress**

Construction in progress represents the costs of acquiring new assets that have not yet been fully installed or the costs of construction that have not yet been fully completed. Construction in progress is stated at cost, which includes all necessary costs to construct, repair, renovate, expand, or re-equip the projects with technologies, such as construction costs, tools and equipment costs, project management costs, construction consulting costs, and borrowing costs that are eligible for capitalization.

Construction in progress will be transferred to the appropriate fixed asset account when these assets are fully installed or the construction project is fully completed, and depreciation of these assets will commence when they are ready for their intended use.

Construction costs are recognized as expenses when such costs do not meet the conditions to be recognized as fixed assets.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.8 Borrowing costs**

Borrowing costs consist of interest and other costs that the Company incurs in connection with the borrowing of funds.

Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that necessarily take a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the respective asset.

**3.9 Leased assets**

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

A lease is classified as a finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership of the asset to the lessee. All other leases are classified as operating leases.

*Where the Company is the lessee*

Rentals under operating leases are charged to the separate income statement on a straight-line basis over the term of the lease.

**3.10 Prepaid expenses**

Prepaid expenses are reported as short-term or long-term prepaid expenses on the balance sheet and amortized over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

**3.11 Investments**

*Investment in subsidiaries*

Investment in subsidiaries over which the Company has control is carried at cost.

Distributions from accumulated net profits of the subsidiary arising subsequent to the date of acquisition are recognized in the separate income statement. Distributions from sources which are attributable to period before obtaining controls are considered a recovery of investment and are deducted to the cost of the investment.

*Investment in an associate*

Investments in an associate over which the Company has significant influence are carried at cost.

Distributions from accumulated net profits of the associate arising subsequent to the date of acquisition are recognized in the separate income statement. Distributions from sources which are attributable to period before having significant influence are considered a recovery of investment and are deducted to the cost of the investment.

*Held-for-trading securities and investments in other entities*

Held-for-trading securities and investments in other entities are stated at their acquisition costs.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.11 Investments (continued)**

*Provision for diminution in value of investments*

Provision for diminution in value of the investment is made when there are reliable evidences of the diminution in value of those investments at the balance sheet date.

Increases or decreases to the provision balance are recorded as finance expense in the separate income statement.

*Held-to-maturity investments*

Held-to-maturity investments are stated at their acquisition costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognized as expense in the separate financial statements and deducted against the value of such investments.

**3.12 Payables and accruals**

Payables and accruals are recognized for amounts to be paid in the future for goods and services received, whether or not billed to the Company.

**3.13 Accrual for severance pay**

The severance pay to employee is accrued at the end of each reporting year for employees who have been worked for more than 12 months at the Company. The accrued amount is calculated at the rate of one-half of the average monthly salary for each year of service qualified for severance pay in accordance with the Labour Code and related implementing guidance. The average monthly salary used in this calculation is adjusted at the end of each reporting year following the average monthly salary of the last 6-month period up to the reporting date. Increases or decreases to the accrued amount other than actual payment to employee will be taken to the separate income statement.

This accrued severance pay is used to settle the termination allowance to be paid to employee upon termination of their labour contract following Article 46 of the Labour Code.

**3.14 Foreign currency transactions**

Transactions in currencies other than the Company's reporting currency of VND are recorded at the actual transaction exchange rates at transaction dates which are determined as follows:

- transactions resulting in receivables are recorded at the buying exchange rates of the commercial banks designated for collection; and
- transactions resulting in liabilities are recorded at the selling exchange rates of the transaction of commercial banks designated for payment.

At the end of the year, monetary balances denominated in foreign currencies are translated at the actual exchange rates at the balance sheet date which are determined as follows:

- monetary assets are translated at buying exchange rate of the commercial bank where the Company conduct transactions regularly; and
- monetary liabilities are translated at selling exchange rate of the commercial bank where the Company conduct transactions regularly.

All foreign exchange differences incurred are taken to the separate income statement.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.15 Share capital**

*Ordinary shares*

Ordinary shares with voting right are recognised at par value.

*Share premium*

Share premium is the difference between the par value and the issuance price of the shares, minus the actual expenses incurred for the issuance of the shares.

*Treasury shares*

Own equity instruments which are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in the separate income statement upon purchase, sale, issue or cancellation of the Company's own equity instruments.

**3.16 Appropriation of net profits**

Net profit after tax (excluding negative goodwill arising from a bargain purchase) is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Company maintains the following reserve funds which are appropriated from the Company's net profit as proposed by the Board of Directors and subject to approval by shareholders at the annual general meeting.

*Investment and development fund*

This fund is set aside for use in the Company's expansion of its operation or of in-depth investment.

*Bonus and welfare fund*

This fund is comprised of bonus, welfare fund for employees and bonus fund for the management, which is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits. This fund is presented as a liability on the separate balance sheet.

*Dividends*

Dividends proposed by the Company's Board of Directors are classified as an allocation of undistributed earnings within the equity section of the separate balance sheet, until they have been approved by the Company's shareholders at the Annual General Meeting. When these dividends have been approved by the shareholders and declared, they are recognized as a liability in the separate balance sheet.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**

**3.17 Revenue recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognized:

*Sale of goods*

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

*Rendering of services*

Revenue is recognized when the services have been performed and completed.

*Interest income*

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

*Dividend and Profit Distribution income*

Dividend and profit distribution income are recognized when Company is entitled to receive dividends or when the Company are entitled to receive profits from its capital contributions.

**3.18 Taxation**

*Current income tax*

Current income tax assets and liabilities for the current and prior years are measured at the amount expected to be paid to or recovered from the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the balance sheet date.

Current income tax is charged or credited to the separate income statement, except when it relates to items recognized directly to equity, in which case the current deferred income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Company to set off current income tax assets against current income tax liabilities and when the Company intend to settle its current income tax assets and liabilities on a net basis.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (continued)

**3.18 Taxation** (continued)

*Deferred tax*

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purpose.

Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences and carried forward unused tax losses, to the extent that it is probable that taxable profit will be available against which deductible temporary differences and carried forward unused tax losses can be utilized.

Deferred tax assets are recognized for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized, except where the deferred tax asset in respect of deductible temporary difference which arises from the initial recognition of an asset or liability which at the time of the related transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Previously unrecognized deferred tax assets are re-assessed at each balance sheet date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled based on tax rates and tax laws that have been enacted at the balance sheet date.

Deferred tax is charged or credited to the separate income statement, except when it relates to items recognized directly to equity, in which case the deferred tax is also dealt with in equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Company to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on either the same taxable entity or when the Company intends to either settle current tax liabilities and assets on a net basis or to realize the assets and to settle the liabilities simultaneously, in each future year in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

**3.19 Related parties**

Parties are considered to be related parties of the Company if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Company and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including close members of the family of any such individual.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**4. CASH AND CASH EQUIVALENTS**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Cash on hand	1,533,435,573	1,322,729,968
Cash in banks	52,057,777,845	51,279,669,764
Time deposits at banks	<u>135,000,000,000</u>	<u>249,500,000,000</u>
<b>TOTAL</b>	<b><u>188,591,213,418</u></b>	<b><u>302,102,399,732</u></b>

*Additional information regarding the separate cash flow statement:*

	VND	
	<i>Current year</i>	<i>Previous year</i>
<b>Significant non-cash transactions that will have impact on the separate cash flow statement:</b>		
Dividend declared by net off with receivables	-	2,913,029,929

**5. SHORT-TERM HELD-TO-MATURITY INVESTMENTS**

Held-to-maturity investments represent term deposits at the commercial banks with the original maturity of more than three (3) months and the remaining maturity not exceeding twelve (12) months from the financial year-end and and earn interest at the applicable bank deposit rates.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**6. SHORT-TERM TRADE RECEIVABLES AND ADVANCE TO SUPPLIERS**

**6.1 Short-term trade receivables**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Amount from customers	459,286,909,353	475,302,026,593
<i>South-East Investment Development     Technology Company Limited</i>	<i>45,131,856,249</i>	<i>45,131,856,249</i>
<i>Others</i>	<i>414,155,053,104</i>	<i>430,170,170,344</i>
Amount from a related party (Note 30)	26,943,840	413,649,485
<b>TOTAL</b>	<b>459,313,853,193</b>	<b>475,715,676,078</b>
Provision for doubtful short-term receivables (Note 8)	(59,624,672,966)	(64,418,817,801)
<b>NET</b>	<b>399,689,180,227</b>	<b>411,296,858,277</b>

**6.2 Short-term advances to suppliers**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Viet Son Engineering Joint Stock Company	4,434,147,686	-
Dong A Refrigeration and Electrical Engineering Joint Stock Company	3,531,236,442	267,979,046
Jiangsu Medwell Medical Equipment Company Limited	1,858,333,031	2,715,998,299
Ha Food VN Company Limited	1,351,333,724	-
Dong Nam Company Limited	1,091,279,592	1,091,279,592
Truking Technology Limited	584,887,448	12,995,306,236
Tofflon Science	-	36,272,301,000
Others	27,937,027,961	23,086,564,210
<b>TOTAL</b>	<b>40,788,245,884</b>	<b>76,429,428,383</b>
Provision for doubtful short-term receivables (Note 8)	(1,347,475,772)	(1,371,279,592)
<b>NET</b>	<b>39,440,770,112</b>	<b>75,058,148,791</b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**7. OTHER SHORT-TERM RECEIVABLES**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Accrued interest income	4,957,456,166	2,378,103,423
Advance to employees	349,414,190	782,928,777
Short-term deposit	101,899,952	106,825,952
Others	3,363,746,067	3,252,368,970
<b>TOTAL</b>	<b>8,772,516,375</b>	<b>6,520,227,122</b>
Provision for doubtful short-term receivables (Note 8)	<u>(2,281,861,467)</u>	<u>(2,281,861,467)</u>
<b>NET</b>	<b><u>6,490,654,908</u></b>	<b><u>4,238,365,655</u></b>

**8. PROVISION FOR SHORT-TERM DOUBTFUL RECEIVABLES**

**8.1 Provision for short-term doubtful receivables**

Detail of movements of provision for doubtful short-term receivables:

	VND	
	<i>Current year</i>	<i>Previous year</i>
Beginning balance	(68,071,958,860)	(69,378,783,874)
Add: Provision made during the year	-	(4,571,999,735)
Less: Revert provision during the year	<u>4,817,948,655</u>	<u>5,878,824,749</u>
Ending balance	<u>(63,254,010,205)</u>	<u>(68,071,958,860)</u>

**8.2 Overdue debts**

	VND			
	<i>Debtors</i>			
	<i>South-East Investment Development Technology Company Limited</i>	<i>Kien Tao Limited Company</i>	<i>Other customers</i>	<i>Total</i>
<b>Ending balance</b>				
Cost	45,895,444,249	11,560,756,445	8,247,865,628	65,704,066,322
Provision	<u>(45,895,444,249)</u>	<u>(11,560,756,445)</u>	<u>(5,797,809,511)</u>	<u>(63,254,010,205)</u>
Net amount	<u>-</u>	<u>-</u>	<u>2,450,056,117</u>	<u>2,450,056,117</u>
<b>Beginning balance</b>				
Cost	46,986,723,841	12,339,449,445	13,983,805,762	73,309,979,048
Provision	<u>(46,986,723,841)</u>	<u>(12,339,449,445)</u>	<u>(8,745,785,574)</u>	<u>(68,071,958,860)</u>
Net amount	<u>-</u>	<u>-</u>	<u>5,238,020,188</u>	<u>5,238,020,188</u>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**9. INVENTORIES**

	<i>Ending balance</i>		<i>Beginning balance</i>	
	<i>Cost</i>	<i>Provision</i>	<i>Cost</i>	<i>Provision</i>
	VND			
Raw materials	232,400,880,222	(30,381,868,122)	268,828,343,745	(21,907,801,829)
Finished goods	110,664,290,036	(949,155,812)	184,457,917,747	(3,124,185,961)
Work in process	26,910,964,654	-	28,801,827,215	-
Goods in transit	21,005,148,055	-	40,395,223,790	-
Merchandises	2,806,821,686	(179,006,327)	5,705,158,654	(1,923,956,619)
Tools and supplies	1,470,071,105	-	1,678,354,169	-
<b>TOTAL</b>	<b>395,258,175,758</b>	<b>(31,510,030,261)</b>	<b>529,866,825,320</b>	<b>(26,955,944,409)</b>

Detail of movements of provision for obsolete inventories:

	VND	
	<i>Current year</i>	<i>Previous year</i>
Beginning balance	(26,955,944,409)	(10,510,115,148)
Add: Provision made during the year	(10,097,046,128)	(20,564,518,416)
Less: Revert provision during the year	5,542,960,276	4,118,689,155
Ending balance	<u>(31,510,030,261)</u>	<u>(26,955,944,409)</u>

**10. PREPAID EXPENSES**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
<b>Short term</b>	<b>8,922,293,818</b>	<b>8,607,704,453</b>
Tools and supplies	3,142,995,274	2,494,919,721
Maintenance and repair costs	3,050,224,733	4,016,797,362
Rental	401,900,000	240,000,000
Others	2,327,173,811	1,855,987,370
<b>Long term</b>	<b>41,460,158,966</b>	<b>38,643,130,984</b>
Land rental (*)	29,374,180,800	30,248,346,672
Maintenance and repair	7,681,864,023	5,034,904,647
Tools and supplies	2,693,070,863	3,194,206,392
Others	1,711,043,280	165,673,273
<b>TOTAL</b>	<b>50,382,452,784</b>	<b>47,250,835,437</b>

(\*) The prepaid land rental represented the unamortized balance of advance payments made in accordance with lease contracts signed with Sai Gon – Nhon Hoi Industrial Park Joint Stock Company and will expire on 17 June 2066 and 31 July 2069.

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

B09-DN

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

## 11. TANGIBLE FIXED ASSETS

	Buildings and structures	Machinery and equipment	Means of transportation	Office equipment	Total
<b>Cost:</b>					VND
Beginning balance	232,381,282,565	507,027,407,434	51,052,125,034	19,460,030,651	809,920,845,684
New purchases	609,279,361	17,887,012,150	1,046,296,296	3,906,936,552	23,449,524,359
Construction in progress completed	1,533,316,342	19,119,237,135	-	-	20,652,553,477
Disposal	(175,880,909)	(4,846,363,381)	-	(222,174,546)	(5,244,418,836)
Ending balance	234,347,997,359	539,187,293,338	52,098,421,330	23,144,792,657	848,778,504,684
<i>In which:</i>					
Fully depreciated	116,451,677,119	264,282,357,907	34,840,772,444	16,306,411,633	431,881,219,103
<b>Accumulated depreciation:</b>					
Beginning balance	138,806,941,878	334,168,500,749	39,948,689,928	16,886,620,047	529,810,752,602
Depreciation for the year	15,640,530,407	33,653,526,769	2,169,185,673	1,360,044,708	52,823,287,557
Disposal	(175,880,909)	(4,846,363,381)	-	(222,174,546)	(5,244,418,836)
Ending balance	154,271,591,376	362,975,664,137	42,117,875,601	18,024,490,209	577,389,621,323
<b>Net carrying amount:</b>					
Beginning balance	93,574,340,687	172,858,906,685	11,103,435,106	2,573,410,604	280,110,093,082
Ending balance	80,076,405,983	176,211,629,201	9,980,545,729	5,120,302,448	271,388,883,361
<i>In which:</i>					
Pledged as loan security (Note 19.2)	53,244,561,754	102,934,979,155	460,246,202	3,728,681,157	160,368,468,268

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**12. INTANGIBLE FIXED ASSETS**

	VND		
	<i>Land use rights (*)</i>	<i>Computer software</i>	<i>Total</i>
<b>Cost:</b>			
Beginning balance	56,767,881,650	19,343,111,742	76,110,993,392
New purchases	-	1,524,113,000	1,524,113,000
Construction in progress completed	<u>25,575,711,296</u>	<u>-</u>	<u>25,575,711,296</u>
Ending balance	<u>82,343,592,946</u>	<u>20,867,224,742</u>	<u>103,210,817,688</u>
<i>In which:</i>			
Fully depreciated	-	14,092,811,300	14,092,811,300
<b>Accumulated amortization:</b>			
Beginning balance	2,930,983,237	16,356,076,415	19,287,059,652
Amortization for the year	<u>228,189,055</u>	<u>1,456,452,006</u>	<u>1,684,641,061</u>
Ending balance	<u>3,159,172,292</u>	<u>17,812,528,421</u>	<u>20,971,700,713</u>
<b>Net carrying amount:</b>			
Beginning balance	<u>53,836,898,413</u>	<u>2,987,035,327</u>	<u>56,823,933,740</u>
Ending balance	<u>79,184,420,654</u>	<u>3,054,696,321</u>	<u>82,239,116,975</u>

(\*) Land use rights represent land use rights of branch offices.

**13. CONSTRUCTION IN PROGRESS**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Hi-tech pharmaceutical factory	503,589,550,775	158,721,743,664
Powder injection line	23,496,972,309	28,689,372,308
Ho Chi Minh Branch Office	-	24,924,000,000
Others	<u>12,041,798,208</u>	<u>20,448,507,415</u>
<b>TOTAL</b>	<b><u>539,128,321,292</u></b>	<b><u>232,783,623,387</u></b>

**14. LONG-TERM INVESTMENTS**

	VND	
	<i>Ending balance</i>	<i>Beginning balance</i>
Investment in subsidiaries	35,000,000,000	35,000,000,000
Investment in an associate	92,868,048,000	92,868,048,000
Investments in other entities	<u>3,513,534,971</u>	<u>3,513,534,971</u>
<b>TOTAL</b>	<b><u>131,381,582,971</u></b>	<b><u>131,381,582,971</u></b>
Provision for long-term investments	<u>(2,000,000,000)</u>	<u>(2,000,000,000)</u>
<b>NET</b>	<b><u>129,381,582,971</u></b>	<b><u>129,381,582,971</u></b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**14. LONG-TERM INVESTMENTS (continued)**

Name	Business activities	Status	Beginning and ending balances	
			% ownership	Cost of investment (VND)
<b>Subsidiaries:</b>				
Bidiphar Trading Company Limited	Trading in medicines, herbs, medical equipment	Operating	100.00	30,000,000,000
Bidiphar Organic Medicine Company Limited	Production of medicines, chemicals and herbs	Operating	100.00	5,000,000,000
<b>TOTAL</b>				<b><u>35,000,000,000</u></b>
<b>An associate: (*)</b>				
Bidiphar Rubber Joint Stock Company	Rubber manufacturing	Operating	33.58	<u>92,868,048,000</u>
<b>Other entities: (*)</b>				
Thien Phuc Joint Stock Company	Provide equipment, anti-lightning system	Operating	10.00	2,000,000,000
Nghe An Pharmaceutical Medical Material and Equipment JSC	Pharmaceutical manufacturing	Operating	3.40	1,513,534,971
<b>TOTAL</b>				<b><u>3,513,534,971</u></b>
Provision for investments in other entities				<u>(2,000,000,000)</u>
<b>NET</b>				<b><u>1,513,534,971</u></b>

(\*) Fair value of these investments are not determined as at 31 December 2025 due to unavailability of market information. However, based on the current operation position of these companies, the Management believed that the fair value of those investments was higher than their book value.

**15. SHORT-TERM TRADE PAYABLES AND ADVANCES FROM CUSTOMERS**

**15.1 Short-term trade payables**

	VND	
	Ending balance	Beginning balance
Amount from suppliers	205,642,607,143	152,310,967,712
Tofflon Science	33,352,106,062	3,020,202,000
Bach Khoa Mechanical and Refrigeration Engineering Co., Ltd.	19,264,779,810	-
Truking Technology Limited	12,591,236,550	3,113,579,550
Trung Son Technology Co., Ltd	1,195,608,000	459,428,000
Aristopharma Ltd.	-	13,793,220,000
Others	137,734,490,721	131,924,538,162
Amount from a related party (Note 30)	<u>153,713,002</u>	<u>34,473,600</u>
<b>TOTAL</b>	<b><u>204,291,934,145</u></b>	<b><u>152,345,441,312</u></b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**15. SHORT-TERM TRADE PAYABLES AND ADVANCES FROM CUSTOMERS (continued)**

**15.2 Short-term advances from customers**

	VND	
	Ending balance	Beginning balance
VP-Pharma Pharmaceutical JSC	5,940,546,470	1,396,512,100
T&T Equipment Joint Stock Company	2,425,500,000	-
Sundial Pharma Joint Stock Company	1,457,124,271	3,444,824,049
Rexton JSC	1,381,288,200	1,626,195,000
Others	<u>4,216,310,165</u>	<u>9,496,996,192</u>
<b>TOTAL</b>	<b><u>15,420,769,106</u></b>	<b><u>15,964,527,341</u></b>

**16. STATUTORY OBLIGATIONS**

	VND			
	Beginning balance	Increase in year	Decrease in year	Ending balance
Corporate income tax	19,718,128,295	54,329,614,225	(23,719,245,066)	50,328,497,454
Value-added tax ("VAT")	884,909,190	16,920,583,945	(17,647,412,645)	158,080,490
Personal income tax ("PIT")	2,908,517,793	26,510,912,740	(28,275,111,047)	1,144,319,486
PIT receivable	(3,296,478)	(45,074,279)	-	(48,370,757)
VAT imported goods	(1,350,975,545)	31,871,603,227	(30,817,762,197)	(297,134,515)
Import tax	-	467,677,048	(467,677,048)	-
Others	<u>3,725,552,771</u>	<u>6,610,795,413</u>	<u>(9,846,357,289)</u>	<u>489,990,895</u>
<b>TOTAL</b>	<b><u>25,882,836,026</u></b>	<b><u>136,666,112,319</u></b>	<b><u>(110,773,565,292)</u></b>	<b><u>51,775,383,053</u></b>
<i>In which:</i>				
Receivable	1,354,272,023			358,416,341
Payable	27,237,108,049			52,133,799,394

**17. SHORT-TERM ACCRUED EXPENSES**

	VND	
	Ending balance	Beginning balance
Selling expenses accruals	22,538,050,984	17,796,641,461
Other expense	<u>1,414,590,033</u>	<u>452,344,852</u>
<b>TOTAL</b>	<b><u>23,952,641,017</u></b>	<b><u>18,248,986,313</u></b>

**18. SHORT-TERM OTHER PAYABLES**

	VND	
	Ending balance	Beginning balance
Remuneration for Board of Directors ("BOD"), and Audit Committee	6,407,417,951	6,498,614,659
Dividend declared	1,600,459,750	121,478,825
Thien Phuc Charity Foundation	1,028,022,166	1,750,718,610
Others	<u>555,463,058</u>	<u>310,274,560</u>
<b>TOTAL</b>	<b><u>9,591,362,925</u></b>	<b><u>8,681,086,654</u></b>

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

B09-DN

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

## 19. LOANS

	Beginning balance	Drawdown	Repayment	Reclassification	Ending balance
<b>Short-term loan</b>	<b>35,913,500,637</b>	<b>139,894,808,772</b>	<b>(148,593,533,781)</b>	<b>16,000,000,000</b>	<b>43,214,775,628</b>
Loan from banks (Note 19.1)	19,913,500,637	139,894,808,772	(132,593,533,781)	-	27,214,775,628
Current portion of long-term loan (Note 19.2)	16,000,000,000	-	(16,000,000,000)	16,000,000,000	16,000,000,000
<b>Long-term loan</b>	<b>28,000,000,000</b>	<b>120,000,000,000</b>	<b>-</b>	<b>(16,000,000,000)</b>	<b>132,000,000,000</b>
Loan from a related party (Note 19.2)	28,000,000,000	120,000,000,000	-	(16,000,000,000)	132,000,000,000
<b>TOTAL</b>	<b>63,913,500,637</b>	<b>259,894,808,772</b>	<b>(148,593,533,781)</b>	<b>-</b>	<b>175,214,775,628</b>

VND

### 19.1 Short-term loans from banks

Banks	Ending balance	Maturity date	Interest rate	Purpose	Description of collateral
Joint Stock Commercial Bank for Investment and Development of Vietnam – Binh Dinh Branch	VND 14,268,551,500	13 February 2026	% p.a. 4.7	Finance working capital requirements	Unsecured
Joint Stock Commercial Bank for Foreign Trade of Vietnam – Quy Nhon Branch	12,946,224,128	8 March 2026	6.6	Finance working capital requirements	Unsecured
	<b>27,214,775,628</b>				

### 19.2 Long-term loan

Lender	Ending balance	Maturity date	Interest rate	Purpose	Description of collateral
Gia Lai Development Investment Fund (formerly known as Binh Dinh Development Investment Fund) (Note 30)	VND 148,000,000,000	From 31 March 2026 to 20 August 2032	% p.a. 5.5 - 7.0	Finance its pharmaceutical factory at Nhon Hoi Industrial Park	All future assets of the Bidiphar High-Tech Pharmaceutical Factory Project: Cancer Treatment Medicine Factory (Note 11)

In which:

Current portion	16,000,000,000
Non-current portion	132,000,000,000

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**20. BONUS AND WELFARE FUND**

				VND
	<i>Bonus fund</i>	<i>Welfare fund</i>	<i>Bonus fund for management</i>	<i>Total</i>
Beginning balance	35,444,876,372	61,744,636,563	16,057,321,010	113,246,833,945
Profit after tax appropriation ( <i>Note 22.1</i> )	14,597,008,230	14,597,008,230	5,838,803,292	35,032,819,752
Other increase	14,040,000	6,600,000	-	20,640,000
Reclassification	158,700,000	(158,700,000)	-	-
Utilisation	<u>(1,196,700,000)</u>	<u>(2,959,135,256)</u>	<u>(16,033,200,000)</u>	<u>(20,189,035,256)</u>
Ending balance	<u>49,017,924,602</u>	<u>73,230,409,537</u>	<u>5,862,924,302</u>	<u>128,111,258,441</u>

**21. SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT FUND**

			VND
	<i>Scientific and technological development fund</i>	<i>Scientific and technological development fund formed fixed assets</i>	<i>Total</i>
Beginning balance	88,177,085,243	19,466,934,377	107,644,019,620
Profit before tax appropriation ( <i>Note 26</i> )	50,000,000,000	-	50,000,000,000
Other decrease	(22,228,023,286)	149,000,000	(22,079,023,286)
Depreciation charged to scientific and technological development fund	<u>-</u>	<u>(2,794,666,258)</u>	<u>(2,794,666,258)</u>
Ending balance	<u>115,949,061,957</u>	<u>16,821,268,119</u>	<u>132,770,330,076</u>

# Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

B09-DN

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

## 22. OWNERS' EQUITY

### 22.1 Increase and decrease in owners' equity

	Share capital	Share premium	Treasury share	Investment and development fund	Undistributed earnings	Total	VND
<b>Previous year</b>							
Beginning balance	748,835,590,000	20,921,442,000	(1,952,796,558)	174,168,770,079	415,811,782,330	1,357,784,787,851	
Net profit for the year	-	-	-	-	267,916,044,806	267,916,044,806	
Appropriation to investment and development fund	-	-	-	27,518,194,919	(27,518,194,919)	-	
Appropriation to bonus and welfare funds	-	-	-	-	(33,021,833,902)	(33,021,833,902)	
Stock dividends	187,102,880,000	-	-	-	(187,102,880,000)	-	
Board of Directors' remuneration	-	-	-	-	(5,503,638,984)	(5,503,638,984)	
Ending balance	935,938,470,000	20,921,442,000	(1,952,796,558)	201,686,964,998	430,581,279,331	1,587,175,359,771	
<b>Current year</b>							
Beginning balance	935,938,470,000	20,921,442,000	(1,952,796,558)	201,686,964,998	430,581,279,331	1,587,175,359,771	
Issue Employee Stock Ownership Plan (Note 22.2)	9,355,000,000	-	-	-	-	9,355,000,000	
Net profit for the year	-	-	-	-	292,775,724,603	292,775,724,603	
Appropriation to investment and development fund	-	-	-	29,194,016,460	(29,194,016,460)	-	
Appropriation to bonus and welfare funds	-	-	-	-	(35,032,819,752)	(35,032,819,752)	
Dividends declared	-	-	-	-	(187,107,524,000)	(187,107,524,000)	
Board of Directors' remuneration	-	-	-	-	(5,838,803,292)	(5,838,803,292)	
Ending balance	945,293,470,000	20,921,442,000	(1,952,796,558)	230,880,981,458	466,183,840,430	1,661,326,937,330	

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**22. OWNERS' EQUITY** (continued)

**22.2 Capital transactions with owners and distribution of dividends, profits**

	VND	
	Current year	Previous year
<b>Contributed capital</b>		
Beginning balance	935,938,470,000	748,835,590,000
Issue Employee Stock Ownership Plan (i)	9,355,000,000	-
Stock dividends	-	187,102,880,000
Ending balance	<u>945,293,470,000</u>	<u>935,938,470,000</u>
<b>Dividends</b>		
Dividends declared (ii)	187,107,524,000	187,102,880,000
Dividends by shares	-	187,102,880,000
Dividends paid by cash (ii)	185,628,543,075	9,933,200

(i) On 27 August 2025, the Company announced the completion of the issuance of 935,500 shares at an issue price of VND 10,000 per share to its employees under the employee stock option program. This share issuance has been approved by shareholders pursuant to Resolution No. 749/NQ-ĐHĐCĐ dated 27 April 2024 of the 2024 Annual General Meeting of Shareholders, Resolution No. 56/NQ-ĐHĐCĐ 2025 dated 26 April 2025, and Board of Directors Decisions No. 85/QĐ-HĐQT dated 4 June 2025, No. 86/QĐ-HĐQT dated 4 June 2025, No. 87/QĐ-HĐQT dated 4 June 2025, and No. 96/QĐ-HĐQT dated 27 June 2025. Accordingly, the Company's share capital increased from VND 935,938,470,000 to VND 945,293,470,000. According to Official Letter No. 4861/UBCK-QLCB dated 29 August 2025, the State Securities Commission ("SSC") announced that it had received the Company's report on the issuance of 935,500 shares to its employees under the aforementioned employee stock option program. The Company received the 14th amended Business Registration Certificate dated 11 September 2025, approved by the Department of Enterprises and Collective Economy under the Gia Lai Provincial Department of Finance, regarding the adjustment of the new capital amount.

(ii) In accordance with the Resolution No. 56/NQ-ĐHĐCĐ 2025 dated 26 April 2025, the General Meeting of Shareholders approved the plan for the dividend of 2025 with each share receiving 20% of par value of share and in accordance with Announcement No. 1189/TB-DBD dated 4 July 2025 regarding the payment of cash dividends.

**22.3 Share capital**

	Number of shares	
	Ending balance	Beginning balance
Authorized shares	94,529,347	93,593,847
Shares issued and fully paid		
<i>Ordinary shares</i>	94,529,347	93,593,847
Treasury shares		
<i>Ordinary shares</i>	(40,085)	(40,085)
Shares in circulation		
<i>Ordinary shares</i>	94,489,262	93,553,762

Each ordinary share with par value of VND 10,000. The holders of the ordinary shares are entitled to receive dividends as and when declared by the Company. Each ordinary share carries one vote per share without restriction.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**22. OWNERS' EQUITY** (continued)

**22.4 Contributed share capital**

	<u>Ending balance</u>		<u>Beginning balance</u>	
	<i>Amount</i>	<i>Ownership</i>	<i>Amount</i>	<i>Ownership</i>
	<i>VND</i>	<i>%</i>	<i>VND</i>	<i>%</i>
Binh Dinh Development Investment Fund	124,856,060,000	13.21	124,856,060,000	13.34
KWE Beteiligungen AG	100,535,500,000	10.64	93,685,500,000	10.01
Others	719,501,060,000	76.11	716,996,060,000	76.61
Treasury shares	400,850,000	0.04	400,850,000	0.04
<b>TOTAL</b>	<b>945,293,470,000</b>	<b>100.00</b>	<b>935,938,470,000</b>	<b>100.00</b>

**23. OTHER FUNDS**

Other funds represent funds allocated by the Department of Science and Technology of Binh Dinh Province ("TECHBID") in relation to the contract of "Research and development and apply technology to produce some drugs used cancer treatment at Binh Dinh Pharmaceutical and Medical Equipment", "Researching and developing of dosage forms and assessment of the effects of remedies for treating injuries in traditional martial arts of Binh Dinh"; and contracts for researching, developing and applying of propagation, planting and processing of a number of medicinal plants.

**24. REVENUES**

**24.1 Revenues from sale of goods and rendering of services**

	<i>VND</i>	
	<i>Current year</i>	<i>Previous year</i>
<b>Gross revenue</b>	<b>1,865,297,612,813</b>	<b>1,740,554,933,937</b>
<i>Of which:</i>		
<i>Sales of pharmaceuticals</i>	1,838,878,907,974	1,713,312,693,266
<i>Sales of materials, packaging, tools and supplies</i>	13,348,581,085	18,586,867,418
<i>Sales of medical supplies</i>	4,674,951,472	8,252,769,927
<i>Others</i>	8,395,172,282	402,603,326
<b>Less</b>	<b>(75,240,459,887)</b>	<b>(82,622,992,054)</b>
Trade discounts and sale allowances	(68,604,889,559)	(79,141,380,130)
Sales returns	(6,635,570,328)	(3,481,611,924)
<b>NET REVENUE</b>	<b>1,790,057,152,926</b>	<b>1,657,931,941,883</b>
<i>In which:</i>		
<i>Sales to other parties</i>	1,684,666,527,498	1,557,431,138,660
<i>Sales to a related party (Note 30)</i>	105,390,625,428	100,500,803,223



NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**24. REVENUES** (continued)

**24.2 Finance income**

	VND	
	<i>Current year</i>	<i>Previous year</i>
Dividends income and profit distribution	21,908,700,196	30,193,963,241
Interest income	19,670,456,373	11,164,456,054
Foreign exchange gains	<u>5,153,319,762</u>	<u>1,754,141,812</u>
<b>TOTAL</b>	<b><u>46,732,476,331</u></b>	<b><u>43,112,561,107</u></b>

**25. COST OF GOODS SOLD AND SERVICE RENDERED**

	VND	
	<i>Current year</i>	<i>Previous year</i>
Cost of pharmaceuticals sold	912,184,861,678	817,636,482,119
Cost of materials, packaging, tools and supplies sold	18,819,258,291	33,123,410,276
Cost of medical supplies sold	3,288,874,907	8,051,087,988
Others	<u>5,991,811,391</u>	<u>355,811,898</u>
<b>TOTAL</b>	<b><u>940,284,806,267</u></b>	<b><u>859,166,792,281</u></b>

**26. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSES**

	VND	
	<i>Current year</i>	<i>Previous year</i>
<b>Selling expenses</b>	<b>397,843,883,285</b>	<b>385,686,363,721</b>
Labor cost	183,989,901,835	191,295,723,385
External services expenses	53,934,634,739	56,013,899,698
Depreciation	3,088,266,715	3,213,450,544
Others	156,831,079,996	135,163,290,094
<b>General and administrative expenses</b>	<b>137,590,473,577</b>	<b>120,978,955,274</b>
Scientific and technological development expense ( <i>Note 21</i> )	50,000,000,000	23,000,000,000
Labor cost	47,330,719,686	45,916,722,901
External services expenses	16,815,969,390	11,709,541,137
Depreciation and amortization	8,748,122,086	9,935,004,418
Reversal of provision for doubtful short-term receivables	(4,817,948,655)	(330,125,014)
Others	<u>19,513,611,070</u>	<u>30,747,811,832</u>
<b>TOTAL</b>	<b><u>535,434,356,862</u></b>	<b><u>506,665,318,995</u></b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**27. FINANCE EXPENSES**

	VND	
	<i>Current year</i>	<i>Previous year</i>
Payment discount	7,224,408,063	7,244,879,653
Interest expenses	3,846,557,387	4,058,137,920
Foreign exchange loss	2,508,913,003	2,701,633,482
Provision for long term investment devaluation	-	2,000,000,000
<b>TOTAL</b>	<b><u>13,579,878,453</u></b>	<b><u>16,004,651,055</u></b>

**28. PRODUCTION AND OPERATING COSTS**

	VND	
	<i>Current year</i>	<i>Previous year</i>
Raw materials	585,492,822,947	633,413,443,791
Labor costs	331,502,805,362	327,787,097,193
External services expenses	144,814,442,876	142,064,859,696
Depreciation and amortization	50,867,179,027	48,014,021,405
(Reversal) provision	(263,862,803)	16,115,704,247
Other expenses	229,588,533,038	191,763,335,031
<b>TOTAL</b>	<b><u>1,342,001,920,447</u></b>	<b><u>1,359,158,461,363</u></b>

**29. CORPORATE INCOME TAX**

The Company has the obligation to pay corporate income tax ("CIT") at the rate of:

- normal CIT rate 20% of taxable profits earned from manufacturing activities of Nguyen Thai Hoc Factory; and
- an exemption from CIT for four (4) years commencing from the first year in which a taxable profit is earned (2023), and a 50% reduction of the applicable CIT tax rate for the following nine (9) years of taxable profits earned from manufacturing activities of Nhon Hoi Factory.

The tax returns filed by the Company are subject to examination by the tax authorities. As the application of tax laws and regulations is susceptible to varying interpretations, the amounts reported in the separate financial statements could change at a later date upon final determination by the tax authorities.

**29.1 CIT expenses**

	VND	
	<i>Current year</i>	<i>Previous year</i>
Current tax expense	54,301,611,629	51,718,128,295
Adjustment for under accrual of tax from prior years	28,002,596	1,202,071,012
	<u>54,329,614,225</u>	<u>52,920,199,307</u>
Deferred tax income	(2,537,964,929)	(5,340,941,441)
<b>TOTAL</b>	<b><u>51,791,649,296</u></b>	<b><u>47,579,257,866</u></b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**29. CORPORATE INCOME TAX** (continued)

**29.1 CIT expenses** (continued)

Reconciliation between CIT expenses and the accounting profit multiplied by CIT rate is presented below:

	VND	
	<i>Current year</i>	<i>Previous year</i>
<b>Accounting profit before tax</b>	<b><u>344,567,373,899</u></b>	<b><u>315,495,302,672</u></b>
At applicable CIT rate to the Company	68,913,474,780	63,099,060,534
<i>Adjustment:</i>		
Exemption income	(13,741,119,602)	(12,755,358,591)
Non-deductible expenses	988,930,741	2,072,277,559
Dividends income	(4,381,740,039)	(6,038,792,648)
Unrecognised deferred tax relating to temporary differences	(15,899,180)	-
Adjustment for under accrual of tax from prior years	<u>28,002,596</u>	<u>1,202,071,012</u>
<b>CIT expenses</b>	<b><u>51,791,649,296</u></b>	<b><u>47,579,257,866</u></b>

**29.2 Current tax**

The current tax payable is based on taxable income for the year. The taxable income of the Company for the year differs from profit as reported in the separate income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are not taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted by the balance sheet date.

**29.3 Deferred tax**

The deferred tax assets recognized by the Company, and the movements thereon, are as follows:

	VND			
	<u>Separate balance sheet</u>		<u>Separate income statement</u>	
	<i>Ending balance</i>	<i>Beginning balance</i>	<i>Current year</i>	<i>Previous year</i>
Depreciation	7,394,572,128	5,872,120,082	1,522,452,046	1,528,802,864
Provision for obsolete inventories	6,302,006,052	5,391,188,882	910,817,170	3,289,165,852
Provision for severance allowance	1,558,112,458	1,453,416,745	104,695,713	122,972,725
Provision for long-term investment	<u>400,000,000</u>	<u>400,000,000</u>	-	400,000,000
<b>Deferred tax assets</b>	<b><u>15,654,690,638</u></b>	<b><u>13,116,725,709</u></b>		
<b>Deferred tax income</b>			<b><u>2,537,964,929</u></b>	<b><u>5,340,941,441</u></b>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 30. TRANSACTIONS WITH RELATED PARTIES

List of related parties which have a controlling relationship with the Company and related parties which have transactions with the Company during the year and as at 31 December 2025 is as follows:

<i>Related parties</i>	<i>Relationship</i>
Gia Lai Development Investment Fund (formerly known as Binh Dinh Development Investment Fund)	Major shareholder
KWE Beteiligungen AG	Major shareholder
Bidiphar Trading Company Limited	Subsidiary
Bidiphar Organic Medicine Limited Company	Subsidiary
Bidiphar Rubber Joint Stock Company	Associate

Significant transactions with related parties during the current year and previous year were as follows:

<i>Related parties</i>	<i>Transactions</i>	<i>Current year</i>	<i>Previous year</i>
			<i>VND</i>
Bidiphar Trading Company Limited	Sale of goods	105,702,976,044	100,609,554,191
	Sale deduction	364,090,136	108,750,968
	Profit distribution	7,617,922,196	12,124,780,741
	Purchase of goods	54,321,126	-
Gia Lai Development Investment Fund	Drawdown of loan	120,000,000,000	-
	Repayment of loan	16,000,000,000	16,000,000,000
	Interest expense	3,831,229,000	3,811,068,000
	Interest expense payable	240,688,000	-
	Dividend paid	18,737,100,000	24,971,210,000
Bidiphar Organic Medicine Limited Company	Purchase of goods	657,127,101	475,720,256
	Sale of goods	51,739,520	-
Bidiphar Rubber Joint Stock Company	Dividend received	14,290,778,000	17,863,472,500

Amounts due to and due from related parties at the balance sheet date were as follows:

<i>Related parties</i>	<i>Transaction</i>	<i>Ending balance</i>	<i>Beginning balance</i>
			<i>VND</i>
<b>Short-term trade receivable (Note 6.1)</b>			
Bidiphar Organic Medicine Limited Company	Sale of goods	26,943,840	-
Bidiphar Trading Company Limited	Sale of goods	-	413,649,485
<b>TOTAL</b>		<b>26,943,840</b>	<b>413,649,485</b>
<b>Short-term trade payable (Note 15.1)</b>			
Bidiphar Organic Medicine Limited Company	Purchase of goods	153,713,002	34,473,600
<b>Loan (Note 19.2)</b>			
Gia Lai Development Investment Fund	Loan	148,000,000,000	44,000,000,000

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**30. TRANSACTIONS WITH RELATED PARTIES** (continued)

Details of salaries, bonus and remuneration for the members of the Board of Directors ("BOD"), and the management and the internal audit committee under BOD are as follows:

<i>Individuals</i>	<i>Title</i>	<i>VND</i>	
		<i>Current year</i>	<i>Previous year</i>
Ms Pham Thi Thanh Huong	General Director/ Member of BOD	8,334,958,642	3,872,050,000
Mr Nguyen Ngoc Dung	Deputy General Director/ Member of BOD	5,038,977,580	3,146,191,596
Ms Banh Thi Ngoc Quynh	Deputy General Director	3,441,175,397	2,270,030,000
Mr Huynh Ngoc Oanh	Deputy General Director (to 1 January 2025)	1,665,500,000	2,842,700,000
Mr Truong Thanh Liem	Member of BOD	1,144,406,667	1,383,165,000
Mr Ta Nam Binh	Chairman/ Independent member of BOD	968,000,000	650,000,000
Ms Nguyen Thi Minh Giang	Independent member of BOD/ Chairwoman of Internal Audit	817,000,000	-
Mr Phan Tan Thu	Independent member of BOD/ Member of Internal Audit	767,000,000	30,000,000
Mr Nguyen Tien Hai	Member of BOD	667,000,000	750,000,000
Mr Hoang Van Thang	Independent member of BOD/ Member of Interna Audit (to 27 April 2024)	-	580,000,000
Mr Dau Minh Lam	Member of BOD (to 27 April 2024)	-	550,000,000
<b>TOTAL</b>		<b><u>22,844,018,286</u></b>	<b><u>16,074,136,596</u></b>

**31. OFF BALANCE SHEET ITEMS**

	<i>Ending balance</i>	<i>Beginning balance</i>
Foreign currencies:		
United States dollar (USD)	60,745.43	2,596.70
Euro (EUR)	128.61	145.82

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

### 32. COMMITMENTS

#### *Operating lease commitments*

The Company leases its warehouse and office under operating lease arrangements. The minimum lease commitments at the balance sheet date under the operating lease agreements were as follows:

	<i>Ending balance</i>	<i>Beginning balance</i>
Less than 1 year	659,330,000	1,633,874,832
From 1 year to 5 years	366,000,000	822,000,000
<b>TOTAL</b>	<b><u>1,025,330,000</u></b>	<b><u>2,455,874,832</u></b>

#### *Capital commitments*

As at 31 December 2025, the Company has contractual commitment for the construction of pharmaceutical factory as follows:

	<i>Contracted amount</i>	<i>Recognized amount</i>	<i>Remaining commitment</i>
Bidiphar High-tech pharmaceutical factory	714,222,612,487	503,589,550,775	210,633,061,712
Powder injection line	24,091,972,569	23,496,972,309	595,000,260
<b>TOTAL</b>	<b><u>738,314,585,056</u></b>	<b><u>527,086,523,084</u></b>	<b><u>211,228,061,972</u></b>

### 33. CONTINGENT LIABILITIES

According to the Environmental Protection Law 2020 and Decree No. 08/2022/ND-CP dated 10 January 2022 of the Government detailing the implementation of certain articles of the Environmental Protection Law, manufacturers and importers of certain types of products and packaging will be responsible for recycling those products and packaging according to the mandatory recycling rates as specified in the roadmap, starting from 1 January 2024.

The Company currently engages in the production of commercial packaging for pharmaceutical goods in accordance with the Laws on pharmaceuticals. Accordingly, the Company is identified as being subject to the responsibility of recycling and handling the packaging of its products, and is required to make financial contributions to the Vietnam Environmental Protection Fund according to the mandatory recycling rates and specifications stipulated in Chapter VI, Section 1, Articles 77 to 82 of Decree No. 08/2022/ND-CP.

As of the date of this separate financial statement, the Management is in the process of reliably estimating the value of the potential recycling obligations for packaging that may arise. According to the Management's assessment, the potential recycling obligation for packaging is not material to the separate financial statement.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)  
as at 31 December 2025 and for the year then ended

**34. EVENTS AFTER THE BALANCE SHEET DATE**

There have been no other significant events occurring after the balance sheet date which would require adjustments or disclosures to be made in the separate financial statements of the Company.

Gia Lai Province, Vietnam  
20 March 2026

  
\_\_\_\_\_  
Le Thi Kieu My  
Preparer

  
\_\_\_\_\_  
Do Huy Phuong  
Chief Accountant

  
\_\_\_\_\_  
Pham Thi Thanh Huong  
General Director

